-

Millennium Health Signals Alert™ Shows Carfentanil Extends Deadly Reach

New report identifies concerning uptick in detections of the lethal fentanyl analogue across the U.S. since reemerging in 2023

SAN DIEGO--(BUSINESS WIRE)--Carfentanil was detected 134 times in urine drug test (UDT) results in 21 states from July 2023 to June 2024 (see Map) compared to only 11 times in six states during the preceding three years, according to the latest Millennium Health Signals Alert™.

Fearing a spike in fatal overdoses like those that occurred in 2016-2017 when drug seizure exhibits containing carfentanil surged, public health officials in multiple states, including New York and Ohio, have recently issued warnings about carfentanil’s reemergence.

The analysis of more than 158,000 fentanyl-positive UDT specimens also showed that carfentanil use is associated with significantly higher rates of other drug use, including methamphetamine, xylazine, cocaine, benzodiazepines, and other fentanyl analogues.

“Because carfentanil is 100-times more potent than fentanyl and appearing in so many states, public health authorities are right to be worried,” said Angela Huskey, PharmD, CPE. “Given its history of contributing to overdose outbreaks and the volatility of these trends, we are monitoring carfentanil closely and will provide timely updates to raise awareness of its presence in our communities.”

A copy of the alert can be accessed here.

About Millennium Health

Millennium Health is an accredited specialty laboratory with over 15 years of experience in drug testing. We provide objective information about patients’ recent use of prescription medications and/or illicit drugs which helps clinicians monitor and treat millions of Americans living with chronic pain, substance use disorders, mental health disorders or other health conditions. Our ability to monitor drug use trends allows us to alert clinicians, health agencies and others to real-time drug use changes to help inform more targeted drug overdose prevention and response strategies to save lives.

Contacts

Jody Schneider
Jody.Schneider@millenniumhealth.com
619-917-6810

Millennium Health


Release Versions

Contacts

Jody Schneider
Jody.Schneider@millenniumhealth.com
619-917-6810

More News From Millennium Health

Fentanyl Use Declines in 2024 but People Who Use Fentanyl are Increasingly Using Heroin, Methamphetamine

SAN DIEGO--(BUSINESS WIRE)--The latest Signals Report from Millennium Health highlights that fentanyl detection in urine drug tests has fallen more than 12% from its 2022 peak but fentanyl-associated polysubstance use remains a significant and constantly evolving threat. The analysis of more than 1.4 million urine drug testing results revealed that roughly 93% of the population using fentanyl tested positive for additional substances in 2024, with a notable 14% rise in stimulant use compared to...

New Study Reveals Unprecedented Increases in Fentanyl and Stimulant Concentrations in Urine Drug Test Results

SAN DIEGO--(BUSINESS WIRE)--A study published in JAMA Network Open, led by Andrew Huhn, PhD, MBA, Associate Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine, Kelly Dunn, PhD, MBA, Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine, and co-authored by Millennium Health researchers, illustrates striking increases in the amounts of illicit fentanyl, methamphetamine, and cocaine detected in urine drug testing...

Xylazine Spreads West According to New Millennium Health Signals Alert™

SAN DIEGO--(BUSINESS WIRE)--According to the Millennium Health Signals Alert released today, xylazine use among those who use fentanyl grew substantially in the West in the year after the Office of National Drug Control Policy (ONDCP) designated fentanyl adulterated with xylazine an emerging threat. At the same time, xylazine use also grew in New England, further tightening its grip on the Eastern U.S. where rates of use are approximately double the national rate of 15.6%. “The use of fentanyl...
Back to Newsroom